N-bromomethyl-benzamide | 50628-46-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-bromomethyl-benzamide
• 英文别名: N-Brommethyl-benzamid；N-(Brommethyl)benzamid；N-Brommethyl-benzamid；N-(bromomethyl)benzamide
• CAS: 50628-46-1
• 化学式: C₈H₈BrNO
• 分子量: 214.062
• InChiKey: GKRFBIYATAATQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-bromomethyl-benzamide 在 五溴化磷 作用下， 生成 N,N-Bis(brommethyl)benzamid
  参考文献：
  名称：

  Boehme,H. et al., Liebigs Annalen der Chemie, 1979, p. 1447 - 1455

  摘要：

  DOI：
• 作为产物：
  描述：

  N-羟甲基苯甲酰胺 在 五溴化磷 作用下， 生成 N-bromomethyl-benzamide
  参考文献：
  名称：

  Devlin,C.J.; Walker,B.J., Journal of the Chemical Society. Perkin transactions I, 1974, p. 453 - 460

  摘要：

  DOI：

文献信息

• Conversion of amino acids and dipeptides into their phosphonic analogs
  作者：George Ösapay、Ildikó Szilagyi、Jenö Seres

  DOI：10.1016/s0040-4020(01)86836-8

  日期：1987.1

  Acylamino carboxylic acids were degradated by the Hunsdiecker-reaction; the bromo-derivatives were reacted with NaPO(OC2H5)2. Aminophosphonic acids were obtained by acidic hydrolysis, and half-blocked derivatives by the selective removal of masking substituents. Two phosphonopeptides [e.g. Alafosfalin (4i)] were also prepared by this route.

  酰基氨基羧酸通过Hunsdiecker反应被降解。溴衍生物与NaPO（OC 2 H 5）2反应。通过酸性水解获得氨基膦酸，通过选择性去除掩蔽取代基获得半封闭的衍生物。通过该途径也制备了两个磷酸肽[例如Alafosfalin（4i）]。
• [EN] PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASE
  申请人：SELVITA S A

  公开号：WO2017068064A1

  公开（公告）日：2017-04-27

  Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.

  本申请公开了一种如下所定义的化合物（I）以及包含该化合物的药物组合物。本申请还公开了利用这种药物组合物治疗疾病的用途，包括但不限于用于治疗癌症、代谢性疾病、炎症性疾病、自身免疫疾病和病毒性疾病。本文所披露的化合物是MNK1和/或MNK2激酶的抑制剂。
• [EN] BIARYL PHOSPHODIESTERASE INHIBITORS<br/>[FR] INHIBITEURS BIARYLE DES PHOSPHODIESTÉRASES
  申请人：LEO PHARMA AS

  公开号：WO2011134468A1

  公开（公告）日：2011-11-03

  Novel biaryl compounds with phosphodiesterase inhibitory activity of the general formula (I), wherein R1, R2, R3, X, Y, Z1, Z2, Z3, and Z4 have the meanings defined herein, as well as their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

  具有磷酸二酯酶抑制活性的新型联苯化合物，其一般化学式为（I），其中R1、R2、R3、X、Y、Z1、Z2、Z3和Z4具有本文中定义的含义，以及它们作为治疗炎症性疾病和症状的治疗剂的用途。
• [EN] MATRIPTASE 2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE MATRIPTASE 2 ET LEURS UTILISATIONS
  申请人：DISC MEDICINE INC

  公开号：WO2020072580A1

  公开（公告）日：2020-04-09

  The present invention provides compounds for inhibiting matriptase 2, or a mutant thereof, and compositions and methods of use thereof.

  本发明提供了用于抑制matriptase 2或其突变体的化合物，以及它们的组合物和使用方法。
• [EN] DUAL INHIBITORS OF ADIPOCYTE FATTY ACID BINDING PROTEIN AND KERATINOCYTE FATTY ACID BINDING PROTEIN<br/>[FR] INHIBITEURS DOUBLES DE LA PROTEINE DE LIAISON DES ACIDES GRAS DES ADIPOCYTES ET DE LA PROTEINE DE LIAISON DES ACIDES GRAS DES KERATINOCYTES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003043624A1

  公开（公告）日：2003-05-30

  Compounds that are dual aP2/k-FABP inhibitors are provided having the formula (I), wherein A, B, X, Y, R?1, R2 and R3¿ are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing dual aP2/k-FABP inhibitors alone or in combination with at least one other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

  提供了具有公式（I）的双重aP2 / k-FABP抑制剂的化合物，其中A，B，X，Y，R1，R2和R3如此描述。还提供了一种治疗糖尿病和相关疾病（特别是II型糖尿病）的方法，使用双重aP2 / k-FABP抑制剂单独或与至少一种其他抗糖尿病药物（如二甲双胍，格列比诺，曲格列酮和/或胰岛素）联合使用。